Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD - Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning.

A number of other equities analysts also recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Morgan Stanley cut their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. JPMorgan Chase & Co. increased their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Guggenheim boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald lifted their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $17.63.

Amicus Therapeutics Stock Up 3.1 %

Shares of NASDAQ FOLD traded up $0.30 during trading hours on Tuesday, hitting $10.13. The company had a trading volume of 3,000,240 shares, compared to its average volume of 2,719,382. The stock has a market capitalization of $3.03 billion, a P/E ratio of -29.29 and a beta of 0.60. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57. The firm's 50 day moving average is $10.57 and its 200-day moving average is $10.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 30,401 shares of company stock valued at $339,363. 2.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors have recently modified their holdings of the business. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics in the third quarter valued at about $26,000. Hazlett Burt & Watson Inc. boosted its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in Amicus Therapeutics during the 3rd quarter worth approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.